Health equity in economic and trade policies

With the Biden-Harris Administration taking the United States out of the "blocking" countries, all eyes are now on Europe and Japan among others as momentum grows for text-based negotiations on the temporary TRIPS waiver for combating the Covid-19 pandemic. The World Trade Organisation director-general Ms Okonjo-Iweala met with German Chancellor Angela Merkel and the TRIPS waiver is likely to have been included in the talks cannot be ruled out in the wake of a global call from 100 former leaders, including half of the US Democratic Congressmen and women, Nobel Laureates, and around 400 international civil society organizations, to agree to the TRIPS waiver. The EU's evolving positions seem to be focused on a "third way" approach—promoted by the European Union and several members of the Ottawa Group- that seeks to address issues such as export restrictions, more bilateral and other licensing agreements, and ensuring the supply of vaccines by countries which have huge stocks of unused vaccines. The authors note that the insistence on a "360 degree view" on the waiver could involve a payment from the waiver co-sponsors, as powerful pharmaceutical companies have also stepped up their campaign against the waiver.

After a year of stalled deliberations on the issue of protecting traditional knowledge, genetic resources and traditional cultural expressions, delegates at the World Intellectual Property Organization General Assemblies on 1 October found a compromise text that gives the committee its strongest mandate yet. The new Intergovernmental Committee on Intellectual Property and Genetic Resources, Traditional Knowledge and Folklore (IGC) agreement is to undertake text-based negotiations that will eventually become an ‘international legal instrument (or instruments)’ to ‘ensure the effective protection of’ traditional knowledge, genetic resources and traditional cultural expressions (folklore). It also lists three texts – containing language in the format of a possible draft instrument – that will form the basis of those negotiations, though it does not limit negotiations to just those texts. It also says there will be three inter-sessional working groups during the next biennium to accelerate the work.

A growing concern among those interested in economic development is the realisation that hundreds of billions of dollars are illicitly flowing out of developing countries to tax havens and other financial centres in the developed world. This new book by the World Bank assesses the dynamics of these flows, much of which is from corruption and tax evasion. What causes them, what are their consequences and how might they be controlled? The chapters by authors from a variety of backgrounds, including criminologists and practicing lawyers as well as economists, examine many dimensions of the phenomenon. Some chapters examine major illegal markets (drug trafficking and human smuggling) to assess how they contribute to these flows, while others are concerned with the corporate role in the phenomenon, particularly the possibility that transfer pricing (in which firms set prices for international trade among wholly owned affiliates) might play a major role in moving money illicitly.

On 18 May 2012, a few days before the 2012 World Health Assembly, the permanent mission of Brazil organised an informal meeting on sanitary regulation and how to improve global cooperation among drug regulatory agencies. Margaret Chan, Secretary-General of the World Health Organisation (WHO), discussed the WHO drug prequalification programme, which she said was intended to give the opportunity for manufacturers from low- and middle-income countries to enter the market with straight quality and safety standards, and to enter into fair competition with other manufacturers. Many countries lacked capacity to pre-qualify their medical products, such as vaccines, as they did not have a functional national drug regulatory authority. These authorities often lacked resources and support from government and other stakeholders. Medicins sans Frontiers voiced its support for regional cooperation between regulatory agencies, adding that WHO should continue the development of norms and standards for phamacovigilence and support their implementation at country level. The Indian delegation identified lack of harmonisation of regulatory systems as a challenge and argued for the exchange and sharing of information among drug regulatory agencies.